Samsung Bioepis Taps Harrow to Take Over U.S. Ophthalmic Drug Rights from Biogen

Samsung Bioepis researchers conducting a research (Provided by Samsung Bioepis) / News1
Samsung Bioepis researchers conducting a research (Provided by Samsung Bioepis) / News1

© Copyright by News1. All Rights Reserved.